Agilon Health Inc (NYSE:AGL) has been facing a challenging week with its stock price falling by 6.95% to $12.72 on Wednesday, November 8, 2023, marking a yearly performance decrease of 27.06%. Despite this fall, the company's stock showed resilience by rising to $13.73 before settling at $13.67 on the same day.
The company, having a market capitalization of $5.16 billion, traded 2.87 million shares on Wednesday, a figure that outperforms the volume of 2.84 million reported in the year-ago period. This trading activity happened at a beta value of 0.80, reflecting the stock's relatively low volatility compared to the overall market.
Analysts have given Agilon Health Inc. a consensus Buy recommendation with a mean rating of 1.24 and an expected EPS of -$0.06 for the current quarter. They set Agilon's consensus price target at $24.40, indicating a potential increase of 47.87%. Revenue forecasts for the current quarter stand at $1.14 billion with expected growth of 28.60% in the next quarter.
Despite industry challenges, Agilon has managed to outperform its competitors with a year-to-date growth rate of 34.62%, significantly higher than the industry average of 1.90%. The company's largest shareholder, Clayton, Dubilier & Rice, LLC along with other institutional holders control 108.48% of shares.
The company's financials show an EPS increase for the current fiscal year at 49.52%, forecasted to reach 0.07 in the upcoming year. Insider ownership accounts for 26.09% with institutional ownership at 85.59%.
Agilon's financial health is further indicated by the company's Quick Ratio of 1.50, price-to-sales ratio of 1.23 for the trailing twelve months, and Diluted EPS of -0.22 for the same period. However, the company reported a net margin of -3.95 and a return on equity of -10.03.
Despite the recent decrease in stock price, Agilon Health Inc.'s performance and resilience in the face of industry challenges offer a promising outlook for the future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.